Leica Biosystems, Indica Labs, and Lunit have announced a strategic partnership aimed at enhancing digital pathology through AI-powered image analysis algorithms, particularly for PD-L1 and other immunohistochemistry biomarkers.
This collaboration builds on an existing relationship between Leica Biosystems and Indica Labs, now integrating Lunit’s advanced AI technology into a comprehensive digital pathology ecosystem. The initial product from this partnership is the Lunit SCOPE algorithm, designed specifically to work with Leica's PD-L1 primary antibody.
One of the key challenges in pathology is the variability in biomarker scoring, which often relies on manual evaluations that can be inconsistent and time-consuming. The integration of AI aims to standardize these scoring methods, thereby streamlining the research process in oncology and improving the reliability of biomarker analysis.
The collaboration combines Leica's IHC assay platform, Indica Labs' image management solutions, and Lunit's AI capabilities to create a seamless digital pathology workflow. This initiative underscores a commitment to interoperability in the field, with leaders from each company expressing optimism about the potential impact on patient care and research efficiency.